GBL 310

Drug Profile

GBL 310

Latest Information Update: 12 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Grannus BioSciences
  • Class Anti-inflammatories; Skin disorder therapies; Small molecules
  • Mechanism of Action Caspase 3 stimulants; MAP kinase kinase kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Actinic keratosis

Most Recent Events

  • 20 Feb 2007 Phase-II clinical trials in Actinic keratosis in United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top